⚠️ Updated analysis. The primary endpoints of SOFT (DFS: tamoxifen plus ovarian suppression vs tamoxifen alone) and the combined SOFT+TEXT analysis (DFS: exemestane plus ovarian suppression vs tamoxifen plus ovarian suppression) were previously reported at median follow-up of approximately 5.6 and 5.7 years, respectively. This analysis reports updated efficacy and safety at median follow-up of 8 years (SOFT) and 9 years (combined SOFT+TEXT).
SOFT primary endpoint (DFS, ITT): 8-year DFS 83.2% vs 78.9% (tamoxifen+OFS vs tamoxifen alone) — HR 0.76 (95% CI 0.62–0.93; P=0.009) Combined SOFT+TEXT primary endpoint (DFS, ITT): 8-year DFS 86.8% vs 82.8% (exemestane+OFS vs tamoxifen+OFS) — HR 0.77 (95% CI 0.67–0.90; P<0.001) SOFT overall survival (ITT): 8-year OS 93.3% vs 91.5% (tamoxifen+OFS vs tamoxifen alone) — HR 0.67 (95% CI 0.48–0.92; P=0.01) Safety signal: Musculoskeletal symptoms grade 3 or 4 in 11.4% with exemestane+OFS; osteoporosis (T score <−2.5) in 14.8% with exemestane+OFS
📱 Clinic quick reference: Mobile version — save for point-of-care use
Clinical Bottom Line
With extended follow-up, these companion trials confirm that adding ovarian function suppression to tamoxifen significantly improves both disease-free survival and overall survival in premenopausal women with hormone-receptor–positive early breast cancer. Furthermore, substituting exemestane for tamoxifen in combination with ovarian suppression provides additional disease-free survival benefit — including a reduction in distant recurrence — though without a detectable overall survival advantage over tamoxifen plus ovarian suppression.
The magnitude of benefit from ovarian suppression is most pronounced among women who received adjuvant chemotherapy and remained premenopausal — a younger, higher-risk population. In this chemotherapy-treated cohort, the absolute differences in disease-free survival and overall survival at eight years are clinically substantial. For lower-risk patients who did not receive chemotherapy, the benefits of ovarian suppression are smaller in absolute terms, though hazard ratios remain consistent. These findings have been incorporated into major treatment guidelines and now form the standard-of-care recommendation for premenopausal women with intermediate- to high-risk hormone-receptor–positive breast cancer.
The key practical concern remains the toxicity burden of ovarian suppression — particularly hot flushes, musculoskeletal symptoms, bone loss, sexual dysfunction, and mood disturbance — which must be weighed against the magnitude of benefit for each individual patient. Approximately one in five patients discontinued triptorelin early, and roughly one in four to five discontinued oral endocrine therapy prematurely, underscoring the challenges of tolerability in a young patient population facing five years of medically induced menopause.
Trial Overview
Study Design
- Trial name and registration: SOFT (Suppression of Ovarian Function Trial), NCT00066690; TEXT (Tamoxifen and Exemestane Trial), NCT00066703
- Design: Phase 3, randomized, open-label, updated follow-up analysis
- Randomization: SOFT: 1:1:1 (tamoxifen alone vs tamoxifen+OFS vs exemestane+OFS); TEXT: 1:1 (tamoxifen+OFS vs exemestane+OFS)
- Stratification factors: Receipt of previous chemotherapy (SOFT) or intended use of adjuvant chemotherapy (TEXT); lymph-node status; intended initial ovarian suppression method if assigned (SOFT only)
- Setting: Hormone-receptor–positive operable early breast cancer, adjuvant setting
- Enrollment period: SOFT: December 2003 through January 2011; TEXT: November 2003 through April 2011
This publication reports the prespecified updated analysis of the SOFT and TEXT trials. The primary endpoints of SOFT and the combined SOFT+TEXT analysis were previously reported.
Patient Population
Key eligibility: Premenopausal women with operable breast cancer expressing estrogen or progesterone receptors in at least 10% of cells. In SOFT, patients who received chemotherapy had to remain premenopausal and undergo randomization within 8 months after completing chemotherapy, once a premenopausal estradiol level had been confirmed. Patients who did not receive chemotherapy underwent randomization within 12 weeks after definitive surgery. In TEXT, all patients underwent randomization within 12 weeks after definitive surgery.
Biomarker selection: Hormone-receptor–positive (estrogen or progesterone receptors expressed in at least 10% of cells); documented premenopausal status.
Sample size flow: 5,738 total randomized across both trials → SOFT ITT: 3,047 (from 3,066 randomized); TEXT ITT: 2,660 (from 2,672 randomized); Combined SOFT+TEXT ITT: 4,690.
Baseline Characteristics
Baseline characteristics in this publication are presented by chemotherapy status rather than by treatment arm. Characteristics were well balanced across treatment groups within each trial.
| Characteristic | SOFT — No Chemotherapy (n=1,419) | SOFT — Previous Chemotherapy (n=1,628) |
|---|---|---|
| Median age, yr | 46 | 40 |
| Lymph-node negative, no. (%) | 1,294 (91.2) | 701 (43.1) |
| Lymph-node positive, no. (%) | 125 (8.8) | 927 (56.9) |
| Tumor size ≤2 cm, no. (%) | 1,213 (85.5) | Not individually reported |
| HER2-negative, no. (%) | 1,329 (93.7) | 1,257 (77.2) |
SOFT overall: Node-positive disease in 34.5%; HER2-negative tumors in 84.9%; chemotherapy received in 1,628 (53.4%).
TEXT overall: Chemotherapy received in 1,607 (60.4%).
Combined SOFT+TEXT: HER2-negative disease in 86.0%.
Treatment Protocol
Arm 1 (SOFT only): Tamoxifen Alone (n=1,021 randomized; safety n=1,005)
Tamoxifen at a dose of 20 mg daily for 5 years from randomization.
- Dose and schedule: Tamoxifen 20 mg daily
- Treatment duration: 5 years
- Median treatment duration: Not reported in this publication.
- Early discontinuation of oral endocrine therapy: 22.5%
Arm 2: Tamoxifen Plus Ovarian Suppression (n=1,024 randomized in SOFT; n=1,334 randomized in TEXT; combined safety n=2,326)
Tamoxifen at a dose of 20 mg daily plus ovarian suppression achieved by triptorelin at a dose of 3.75 mg by intramuscular injection every 28 days, bilateral oophorectomy, or ovarian irradiation for 5 years from randomization.
- Dose and schedule: Tamoxifen 20 mg daily + triptorelin 3.75 mg IM every 28 days (or oophorectomy/ovarian irradiation)
- Treatment duration: 5 years
- Early discontinuation of oral endocrine therapy: 19.3%
- Early cessation of triptorelin: 19.0% (combined population)
Arm 3: Exemestane Plus Ovarian Suppression (n=1,021 randomized in SOFT; n=1,338 randomized in TEXT; combined safety n=2,317)
Exemestane at a dose of 25 mg daily plus ovarian suppression achieved by triptorelin at a dose of 3.75 mg by intramuscular injection every 28 days, bilateral oophorectomy, or ovarian irradiation for 5 years from randomization.
- Dose and schedule: Exemestane 25 mg daily + triptorelin 3.75 mg IM every 28 days (or oophorectomy/ovarian irradiation)
- Treatment duration: 5 years
- Early discontinuation of oral endocrine therapy: 23.7%
- Early cessation of triptorelin: 19.0% (combined population)
Efficacy Outcomes
This publication reports the prespecified updated analysis of two separate but related trials. Results are organized by the two primary questions:
- Does adding ovarian suppression to tamoxifen improve outcomes? (SOFT: tamoxifen+OFS vs tamoxifen alone)
- Is exemestane+OFS superior to tamoxifen+OFS? (Combined SOFT+TEXT analysis)
SOFT Primary Endpoint: Disease-Free Survival — Tamoxifen+OFS vs Tamoxifen Alone
Definition: Survival free of the first occurrence of invasive recurrence of breast cancer (local, regional, or distant), invasive contralateral breast cancer, a second (nonbreast) invasive cancer, or death without recurrence or a second cancer.
Analysis population: Intention-to-treat (SOFT), N=2,033 (1,015 tamoxifen+OFS; 1,018 tamoxifen alone)
Statistical method: Stratified log-rank test; stratified Cox proportional-hazards regression
Median follow-up: 8 years
Total DFS events in SOFT (all 3 arms): 518. Of these, 279 (53.9%) involved distant sites, 51 (9.8%) were invasive contralateral breast cancers, 105 (20.3%) involved locoregional sites, and the remaining 83 events (16.0%) were second cancers or death without recurrence.
| Tamoxifen Alone (n=1,018) | Tamoxifen+OFS (n=1,015) | Exemestane+OFS (n=1,014) | |
|---|---|---|---|
| 8-year DFS rate | 78.9% | 83.2% | 85.9% |
| DFS events | 208 | 167 | 143 |
Tamoxifen+OFS vs Tamoxifen alone: HR 0.76 (95% CI, 0.62 to 0.93; P=0.009)
This confirms the benefit of adding ovarian suppression to tamoxifen with extended follow-up. The absolute difference of 4.3 percentage points at 8 years is clinically meaningful.
SOFT Secondary Objective: Exemestane+OFS vs Tamoxifen Alone
This comparison was a secondary objective of SOFT. It was not formally tested in the statistical hierarchy; only estimates and 95% CIs are reported.
Exemestane+OFS vs Tamoxifen alone: 8-year DFS 85.9% vs 78.9% — a difference of 7.0 percentage points. HR 0.65 (95% CI, 0.53 to 0.81).
Combined SOFT+TEXT Primary Endpoint: Disease-Free Survival — Exemestane+OFS vs Tamoxifen+OFS
Analysis population: Intention-to-treat (combined SOFT and TEXT), N=4,690 (2,346 exemestane+OFS; 2,344 tamoxifen+OFS)
Median follow-up: 9 years
Total DFS events: 720 (15.4%)
| Tamoxifen+OFS (n=2,344) | Exemestane+OFS (n=2,346) | |
|---|---|---|
| 8-year DFS rate | 82.8% | 86.8% |
| DFS events | 402 | 318 |
Exemestane+OFS vs Tamoxifen+OFS: HR 0.77 (95% CI, 0.67 to 0.90; P<0.001)
The 4.0 percentage-point absolute improvement at 8 years confirms the superiority of exemestane over tamoxifen when combined with ovarian suppression.
Key Secondary Endpoints
Freedom from Distant Recurrence — SOFT
Distant recurrence was reported in 306 of 3,047 patients (10.0%) in SOFT.
| Tamoxifen Alone (n=1,018) | Tamoxifen+OFS (n=1,015) | Exemestane+OFS (n=1,014) | |
|---|---|---|---|
| 8-year rate | 88.4% | 89.4% | 91.2% |
| Events | 115 | 104 | 87 |
Tamoxifen+OFS vs Tamoxifen alone: HR 0.86 (95% CI, 0.66 to 1.13; P=0.28) — not statistically significant.
Exemestane+OFS vs Tamoxifen alone (not formally tested): HR 0.73 (95% CI, 0.55 to 0.96).
The addition of ovarian suppression to tamoxifen did not significantly reduce distant recurrence, but exemestane+OFS showed a lower rate of distant recurrence compared with tamoxifen alone.
Freedom from Distant Recurrence — Combined SOFT+TEXT
Distant recurrence was reported in 433 patients (9.2%) in the combined population.
| Tamoxifen+OFS (n=2,344) | Exemestane+OFS (n=2,346) | |
|---|---|---|
| 8-year rate | 89.7% | 91.8% |
| Events | 239 | 194 |
Exemestane+OFS vs Tamoxifen+OFS: HR 0.80 (95% CI, 0.66 to 0.96; P=0.02)
Overall Survival — SOFT
Total deaths in SOFT: 225 (7.4%)
| Tamoxifen Alone (n=1,018) | Tamoxifen+OFS (n=1,015) | Exemestane+OFS (n=1,014) | |
|---|---|---|---|
| 8-year OS rate (95% CI) | 91.5% (89.4–93.2) | 93.3% (91.4–94.8) | 92.1% (90.0–93.7) |
| Deaths | 88 | 61 | 76 |
Tamoxifen+OFS vs Tamoxifen alone: HR 0.67 (95% CI, 0.48 to 0.92; P=0.01)
Exemestane+OFS vs Tamoxifen alone (not formally tested): HR 0.85 (95% CI, 0.62 to 1.15).
The overall survival benefit of tamoxifen+OFS over tamoxifen alone — a 33% reduction in the hazard of death — is a landmark finding from this updated analysis.
Overall Survival — Combined SOFT+TEXT
Total deaths in the combined population: 320 (6.8%)
| Tamoxifen+OFS (n=2,344) | Exemestane+OFS (n=2,346) | |
|---|---|---|
| 8-year OS rate | 93.3% | 93.4% |
| Deaths | 162 | 158 |
Exemestane+OFS vs Tamoxifen+OFS: HR 0.98 (95% CI, 0.79 to 1.22; P=0.84) — no difference in overall survival.
Exploratory Analyses: SOFT Chemotherapy Cohort
Among the 1,628 patients (53.4%) who received chemotherapy before randomization in SOFT — a younger (median age 40 years), higher-risk population — benefits were magnified:
Disease-free survival at 8 years:
| Tamoxifen Alone | Tamoxifen+OFS | Exemestane+OFS | |
|---|---|---|---|
| 8-year DFS | 71.4% | 76.7% | 80.4% |
| Events | 148 | 120 | 108 |
| HR vs tamoxifen alone (95% CI) | Ref | 0.76 (0.60–0.97) | 0.68 (0.53–0.88) |
Overall survival at 8 years (chemotherapy cohort):
| Tamoxifen Alone | Tamoxifen+OFS | Exemestane+OFS | |
|---|---|---|---|
| 8-year OS | 85.1% | 89.4% | 87.2% |
| Deaths | 83 | 51 | 67 |
| HR vs tamoxifen alone (95% CI) | Ref | 0.59 (0.42–0.84) | 0.79 (0.57–1.09) |
Freedom from distant recurrence at 8 years (chemotherapy cohort):
| Tamoxifen Alone | Tamoxifen+OFS | Exemestane+OFS | |
|---|---|---|---|
| 8-year rate | 80.0% | 82.1% | 84.5% |
| Events | 105 | 93 | 82 |
| HR vs tamoxifen alone (95% CI) | Ref | 0.84 (0.64–1.12) | 0.74 (0.56–0.99) |
HER2-Negative Chemotherapy Cohort in SOFT
Among patients with HER2-negative tumors who received chemotherapy in SOFT — a population where HER2-targeted therapy does not confound outcomes:
8-year DFS: tamoxifen alone 71.9%, tamoxifen+OFS 73.9%, exemestane+OFS 83.1%
8-year freedom from distant recurrence: tamoxifen alone 80.8%, tamoxifen+OFS 79.8%, exemestane+OFS 86.8%
8-year OS: tamoxifen alone 85.2%, tamoxifen+OFS 87.7% (HR 0.70; 95% CI, 0.48 to 1.02), exemestane+OFS 88.7% (HR 0.71; 95% CI, 0.49 to 1.05)
Combined SOFT+TEXT: HER2-Negative Subpopulation
Among patients with HER2-negative disease in the combined analysis (exemestane+OFS n=2,011; tamoxifen+OFS n=2,024):
| Endpoint | Tamoxifen+OFS | Exemestane+OFS | HR (95% CI) |
|---|---|---|---|
| 8-year DFS | 82.7% | 88.1% | 0.70 (0.60–0.83) |
| 8-year freedom from distant recurrence | 89.6% | 93.0% | 0.69 (0.56–0.85) |
| 8-year OS | 93.4% | 94.1% | 0.86 (0.68–1.10) |
Safety
Safety Population
Safety data are from the safety populations across both SOFT and TEXT who initiated protocol-assigned treatment. The tamoxifen-alone group is from SOFT only. The tamoxifen+OFS and exemestane+OFS groups combine patients from both trials.
| Safety Metric | Tamoxifen Alone (n=1,005) | Tamoxifen+OFS (n=2,326) | Exemestane+OFS (n=2,317) |
|---|---|---|---|
| Any targeted AE | 962 (95.7%) | 2,295 (98.7%) | 2,288 (98.7%) |
| Targeted AE grade 3 or 4 | 247 (24.6%) | 721 (31.0%) | 748 (32.3%) |
Serious adverse events, treatment-related adverse events, and discontinuation due to adverse events (as standard safety metrics) were not reported in this publication. Early discontinuation of oral endocrine therapy was 22.5% (tamoxifen alone), 19.3% (tamoxifen+OFS), and 23.7% (exemestane+OFS). Early cessation of ovarian suppression by triptorelin was 19.0% in the combined population.
Grade 3 or 4 Adverse Events of Clinical Significance
The source reports grade 3 and grade 4 combined for all targeted adverse events.
| Adverse Event (Grade 3 or 4) | Tamoxifen Alone (n=1,005) | Tamoxifen+OFS (n=2,326) | Exemestane+OFS (n=2,317) |
|---|---|---|---|
| Hot flushes | 78 (7.8%) | 284 (12.2%) | 234 (10.1%) |
| Musculoskeletal symptoms | 67 (6.7%) | 132 (5.7%) | 263 (11.4%) |
| Hypertension | 57 (5.7%) | 188 (8.1%) | 168 (7.3%) |
| Depression | 41 (4.1%) | 108 (4.6%) | 95 (4.1%) |
| Fatigue | 34 (3.4%) | 70 (3.0%) | 75 (3.2%) |
| Insomnia | 30 (3.0%) | 105 (4.5%) | 89 (3.8%) |
| Dyspareunia | 16 (1.6%) | 35 (1.5%) | 56 (2.4%) |
| Thrombosis or embolism | 17 (1.7%) | 47 (2.0%) | 20 (0.9%) |
| Fracture | 8 (0.8%) | 23 (1.0%) | 37 (1.6%) |
Adverse Events of Special Interest
⚠️ Musculoskeletal Symptoms: Exemestane+OFS Signal
- Grade 3 or 4: 263 (11.4%) with exemestane+OFS vs 132 (5.7%) with tamoxifen+OFS vs 67 (6.7%) with tamoxifen alone
- Clinical implication: Musculoskeletal toxicity is the dominant tolerability concern with aromatase inhibitor–based regimens. This doubles the grade 3/4 rate compared with tamoxifen-based approaches and should be proactively managed with exercise counseling, analgesics, and potential switch to tamoxifen+OFS if intolerable.
⚠️ Osteoporosis: Bone Health Concern
- Osteoporosis (T score <−2.5, grade 2, 3, or 4): 3.9% tamoxifen alone; 7.2% tamoxifen+OFS; 14.8% exemestane+OFS
- Clinical implication: Baseline and serial bone density monitoring is mandatory for all patients receiving ovarian suppression, with bisphosphonate or denosumab prophylaxis considered per institutional protocols — particularly with exemestane+OFS.
Thrombosis or Embolism
- Any grade: tamoxifen alone 22 (2.2%); tamoxifen+OFS 53 (2.3%); exemestane+OFS 27 (1.2%)
- Grade 3 or 4: tamoxifen alone 17 (1.7%); tamoxifen+OFS 47 (2.0%); exemestane+OFS 20 (0.9%)
- Thromboembolic risk is predominantly associated with tamoxifen-containing regimens and is lower with exemestane+OFS.
Deaths
One patient in the tamoxifen group in SOFT had a grade 5 cardiac ischemia or infarction. No other grade 5 targeted adverse events were reported across all groups.
| Tamoxifen Alone | Tamoxifen+OFS | Exemestane+OFS | |
|---|---|---|---|
| Total deaths (SOFT) | 88 | 61 | 76 |
| Total deaths (combined SOFT+TEXT, tamoxifen+OFS vs exemestane+OFS) | — | 162 | 158 |
Treatment-related deaths as a standard safety metric were not reported in this publication.
Subgroup Analyses
SOFT: DFS Subgroups — Tamoxifen+OFS vs Tamoxifen Alone
| Subgroup | T+OFS (events/n) | T Alone (events/n) | HR (95% CI) | Interaction P |
|---|---|---|---|---|
| HER2-positive | NR/119 | NR/117 | 0.41 (0.22–0.75) | P=0.04 |
| HER2-negative | NR/NR | NR/NR | 0.83 (0.67–1.04) | — |
| No chemotherapy | NR/445 | NR/437 | 0.72 (0.48–1.07) | Not reported |
| Previous chemotherapy | NR/NR | NR/NR | 0.88 (0.68–1.15) | — |
SOFT: DFS Subgroups — Exemestane+OFS vs Tamoxifen Alone
| Subgroup | E+OFS (events/n) | T Alone (events/n) | HR (95% CI) | Interaction P |
|---|---|---|---|---|
| HER2-positive | NR/130 | NR/117 | 0.74 (0.45–1.22) | P=0.44 |
| HER2-negative | NR/NR | NR/NR | 0.60 (0.47–0.76) | — |
| No chemotherapy | NR/447 | NR/437 | 0.56 (0.36–0.86) | Not reported |
| Previous chemotherapy | NR/NR | NR/NR | 0.62 (0.46–0.83) | — |
The significant interaction by HER2 status for the tamoxifen+OFS vs tamoxifen alone comparison (P=0.04) suggests that HER2-positive patients may derive particular benefit from ovarian suppression when combined with tamoxifen and trastuzumab.
Combined SOFT+TEXT: HER2-Negative Subpopulation
| Endpoint | E+OFS (n=2,011) | T+OFS (n=2,024) | HR (95% CI) |
|---|---|---|---|
| DFS | — | — | 0.70 (0.60–0.83) |
| Freedom from distant recurrence | — | — | 0.69 (0.56–0.85) |
| OS | — | — | 0.86 (0.68–1.10) |
These subgroup analyses were prespecified and were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating. The HER2-negative analyses were not adjusted for multiple comparisons.
Key Comparator Trials
| Trial | Regimen | Population | Primary Endpoint | Key Result | Reference |
|---|---|---|---|---|---|
| SOFT (this analysis) | Tamoxifen+OFS vs tamoxifen alone | Premenopausal HR+ early BC | DFS at 8 yr | 83.2% vs 78.9%, HR 0.76 (P=0.009) | [1] |
| Combined SOFT+TEXT (this analysis) | Exemestane+OFS vs tamoxifen+OFS | Premenopausal HR+ early BC | DFS at 8 yr | 86.8% vs 82.8%, HR 0.77 (P<0.001) | [1] |
| ABCSG-12 | Goserelin+anastrozole vs goserelin+tamoxifen | Premenopausal HR+ early BC | DFS | See [4]; no DFS benefit for anastrozole; OS numerically favored tamoxifen+OFS | [4] |
| ASTRRA | Tamoxifen+OFS (2 yr) vs tamoxifen alone | Premenopausal HR+ early BC after chemo | DFS at 5 yr | See [5]; DFS improved with OFS addition | [5] |
Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.
Contextual Notes
The SOFT/TEXT results are broadly consistent with the ASTRRA trial, which also demonstrated a DFS benefit from adding ovarian suppression to tamoxifen in premenopausal women who remained premenopausal after chemotherapy [5]. However, the ABCSG-12 trial found no benefit for anastrozole over tamoxifen when both were combined with goserelin, and even suggested a potential OS detriment with anastrozole — a finding that initially raised concern about aromatase inhibitors with ovarian suppression [4]. The SOFT/TEXT data, with their larger sample size and longer follow-up, have been more influential in establishing exemestane+OFS as a preferred option over tamoxifen+OFS in higher-risk patients, though the absence of an OS difference between exemestane+OFS and tamoxifen+OFS in the combined analysis leaves the choice between the two somewhat open.
The critical distinction is that SOFT uniquely provides a tamoxifen-alone comparator arm, enabling direct assessment of the benefit of adding ovarian suppression — a question neither TEXT, ABCSG-12, nor ASTRRA can answer with the same rigor. The overall survival benefit of tamoxifen+OFS over tamoxifen alone (HR 0.67; P=0.01) is among the most clinically important findings from this analysis.
Grey Zones and Unanswered Questions
1. Optimal duration of ovarian suppression is unknown. Both SOFT and TEXT administered ovarian suppression for 5 years. Whether shorter duration (e.g., 2–3 years) provides equivalent benefit — or whether longer durations or sequential strategies with extended endocrine therapy improve outcomes further — remains unanswered.
2. The tamoxifen-alone arm may not reflect current practice. The SOFT trial enrolled patients from 2003 to 2011. During this period, extended adjuvant therapy (10 years of tamoxifen, or switch to aromatase inhibitor after menopause) was not standard. The tamoxifen-alone arm represents 5 years of tamoxifen only, which may underestimate the outcomes achievable with current extended adjuvant strategies.
3. Overall survival data remain immature. The publication acknowledges that "data regarding survival and late adverse events are immature" and that "maximal separation of Kaplan–Meier curves for overall survival has typically occurred more than 10 years after randomization." The OS advantage of tamoxifen+OFS over tamoxifen alone (HR 0.67; P=0.01) could change with further follow-up. The lack of OS difference between exemestane+OFS and tamoxifen+OFS may also evolve.
4. Genomic risk stratification was not available. The trial predates routine use of 21-gene recurrence scores (Oncotype DX) and similar assays for treatment decision-making. It is unclear whether genomic low-risk patients benefit from ovarian suppression, or whether benefit is concentrated in genomically intermediate- and high-risk groups. The recently completed RxPONDER trial and TAILORX provide partial context, but direct integration with SOFT/TEXT data is limited.
5. The exemestane+OFS arm in SOFT showed no significant OS benefit over tamoxifen alone (HR 0.85; 95% CI, 0.62 to 1.15), while tamoxifen+OFS did (HR 0.67; P=0.01). This paradox — better DFS with exemestane+OFS but a significant OS signal only with tamoxifen+OFS — is unexplained and could reflect chance, differences in post-recurrence therapy, or biological factors. It complicates the selection between tamoxifen+OFS and exemestane+OFS for individual patients.
Clinical Implications
Rationale and Clinical Context
Before the SOFT and TEXT trials, the standard adjuvant endocrine therapy for premenopausal women with hormone-receptor–positive early breast cancer was tamoxifen alone for 5 years. The role of ovarian suppression was debated, with older trials producing inconclusive results. SOFT was designed to answer whether adding ovarian suppression to tamoxifen improved outcomes, and TEXT (combined with SOFT) was designed to determine whether exemestane was superior to tamoxifen when both were combined with ovarian suppression.
This updated analysis at 8–9 years confirms three key findings: (1) adding OFS to tamoxifen improves DFS and OS; (2) exemestane+OFS improves DFS and distant recurrence-free survival over tamoxifen+OFS; and (3) no OS difference is detectable between exemestane+OFS and tamoxifen+OFS.
Where This Fits in the Treatment Sequence
These results support a risk-stratified approach to adjuvant endocrine therapy in premenopausal HR+ breast cancer:
- Higher-risk patients (chemotherapy-treated, node-positive, young age, higher-grade tumors): Ovarian suppression with either exemestane or tamoxifen — with exemestane preferred when DFS benefit is prioritized and bone health can be managed.
- Lower-risk patients (no chemotherapy, node-negative, favorable tumor features): Tamoxifen alone remains a reasonable option; the absolute benefit of adding OFS is smaller, and the added toxicity burden must be weighed carefully.
- Current NCCN guidelines recommend considering ovarian suppression in combination with tamoxifen or an aromatase inhibitor for premenopausal women at higher risk of recurrence [3].
Monitoring and Long-Term Follow-Up
- Bone density: Baseline DXA scan and serial monitoring (every 1–2 years) for all patients on OFS, with particular vigilance for exemestane+OFS. Bisphosphonate or denosumab therapy as indicated.
- Cardiovascular risk: Monitoring blood pressure (hypertension grade 3/4: 5.7–8.1% across arms) and cardiovascular risk factors.
- Mood and sexual function: Proactive screening for depression (grade 3/4: 4.1–4.6%), insomnia, and sexual dysfunction — all common and underreported in this population.
- Thromboembolic events: Awareness of tamoxifen-associated thrombosis risk (grade 3/4: 1.7–2.0% with tamoxifen; 0.9% with exemestane+OFS).
- Treatment adherence: With approximately 20% rates of early discontinuation of both oral endocrine therapy and triptorelin, regular adherence counseling and symptom management are essential.
Unanswered Questions
The two most practice-relevant open questions are: (1) whether genomic assays can identify premenopausal patients who do not benefit from ovarian suppression and can safely receive tamoxifen alone, and (2) whether the OS advantage of tamoxifen+OFS over tamoxifen alone persists — and whether an OS benefit of exemestane+OFS eventually emerges — with longer follow-up beyond 10 years.
Regulatory and Guideline Status
Regulatory
- Tamoxifen: FDA-approved for adjuvant treatment of hormone-receptor–positive breast cancer. Well-established indication.
- Exemestane: FDA-approved for adjuvant treatment of postmenopausal women with ER-positive early breast cancer who have received 2–3 years of tamoxifen (sequential switch indication). Use in combination with ovarian suppression in premenopausal women represents guideline-supported practice based on SOFT/TEXT data. Regulatory status should be verified with current FDA/EMA labeling [2].
- Triptorelin (Trelstar): FDA-approved for palliative treatment of advanced prostate cancer. Use for ovarian suppression in breast cancer is guideline-supported but may be considered off-label in some jurisdictions. Goserelin (Zoladex) is FDA-approved for premenopausal breast cancer.
⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.
Guidelines
- NCCN: Recommends considering ovarian suppression with either tamoxifen or an aromatase inhibitor for premenopausal women with hormone-receptor–positive early breast cancer at higher risk of recurrence. Category 1 recommendation for OFS addition based on SOFT/TEXT data [3].
- ASCO/ESMO: Similarly endorse risk-stratified use of ovarian suppression in combination with either tamoxifen or an aromatase inhibitor in premenopausal women.
Companion Diagnostics
No specific companion diagnostic is required beyond standard hormone-receptor testing (ER/PR immunohistochemistry) and confirmation of premenopausal status (estradiol levels).
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.
Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
Disclaimer
This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.
All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.
Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.
Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.
References
- Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018. doi:10.1056/NEJMoa1803164
- Exemestane (Aromasin) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network. Accessed March 2026.
- Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313-320.
- Kim HA, Lee JW, Nam SJ, et al. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial (ASTRRA). J Clin Oncol. 2020;38(5):434-443.